Wenzhou, China · Founded 2016 · In IPO Registration
Developer and manufacturer of innovative ophthalmology therapeutics and ophthalmic formulations designed for anterior and posterior segment eye diseases. Viva Vision Biotech is based in Wenzhou, China and was founded in 2016. Its last reported valuation was $257 million in Nov 2025. It has raised $107 million.
Last reported valuation
$256.6M
Oct 2026
Priced at
—
Total raised
$107.4M
Last round
—
Cap table — not yet on record
Viva Vision Biotech's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Viva Vision Biotech with a free account
·The complete investor list: 26 names
·Watch Viva Vision Biotech: the Monday email on marks, rounds and moves
